Calcineurin and cardiac hypertrophy: Where have we been? Where are we going?

Journal of Physiology

Volumn 541, Issue 1, 2002, Pages 1-8

  Wilkins, Benjamin J ^a,b   Molkentin, Jeffery D ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CALCIUM ION; CYCLOSPORIN A; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE TARGETING; GENETIC MODEL; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WORK; HYPOTHESIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; CALCINEURIN; CARDIOMEGALY; HEART; HUMANS; SIGNAL TRANSDUCTION;

EID: 0037095815     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2002.017129     Document Type: Review

References (96)

1. ANTOS, C. L., McKINSEY, T. A., FREY, N., KUTSCHKE,W., McANALLY,J., SHELTON, J. M., RICHARDSON, J. A., HILL, J. A. & OLSON, E. N. (2002). Activated glycogen synthase-3,β suppresses cardiac hypertrophy in vivo. Proceedings of the National Academy of Sciences of the USA 99, 907-912.
2. BUENO, O. F., WILKINS, B. J., TYMITZ, K. M., GLASCOCK, B. J., KIMBALL, T. F., LORENZ, J. N. & MOLKENTIN, J. D. (2002). Impaired cardiac hypertrophic response in calcineurin Aβ deficient mice. Proceedings of the National Academy of Sciences of the USA 99, 4586-4591.
3. CASAS, C., MARTINEZ, S., PRICHARD, M. A., FUENTES, J. J., NADAL, M., GUIMERÀ, J., ARBONÉS, M., FLÓREZ, J., SORIANO, E., ESTIVILL, X. & ALCÁNTARA, S. (200 1). Dscr1, a novel endogenous inhibitor of calcineurin signaling, is expressed in the primitive ventricle of the heart and during neurogenesis. Mechanisms of Development 101, 289-292.
4. CHOW, C.-W., RINCÓN, M., CAVANAGH, J., DICKENS, M. & DAVIS, R. J. (1997). Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 278,1638-1641.
5. CLAYCOMB, W. C. (1977). Cardiac-muscle hypertrophy. Differentiation and growth of the heart cell during development. Biochemical Journal 168,599-601.
6. CLIPSTONE, N. A. & CRABTREE, G. R. (1992). Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357, 695-697.
7. 2+, calcineurin, and NF-AT. Cell 96, 611-614.
8. DE LA POMPA, J. L., TIMMERMAN, L. A., TAKIMOYO, H., YOSHIDA, H., ELIA, A. J., SAMPER, E., POTTER, J., WAKEHAM, A., MARENGERE, L., LANGILLE, B. L., CRABTREE, G. R. & MAK, T. W. (1998). Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 392,182-186.
9. DE WINDT, L. J., LIM, H. W., BUENO, O. F., LIANG, Q., DELLING, U., BRAZ, J. C., GLASCOCK, B. J., KIMBALL, T. F., DEL MONTE, F., HAJJAR, R. J. & MOLKENTIN, J. D. (2001). Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proceedings of the National Academy of Sciences of the USA 98, 3322-3327.
10. 2-terminal kinase activation in the heart. Journal of Biological Chemistry 275, 13571-13579.
11. DE WINDT, L. J., LIM, H. W., TAIGEN, T., WENCKER, D., CONDORELLI, G., DORN, G. W. II, KITSIS, R. N. & MOLKENTIN, J. D. (2000a). Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo. Circulation Research 86, 255-263.
12. DING, B., PRICE, R. L., BORG, T. K., WEINBERG, E. O., HALLORAN, P. F. & LORELL, B. H. (1999). Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circulation Research 84, 729-734.
13. ERNSBERGER, P., KOLETSKY, R. J., BASKIN, J. S. & COLLINS, L. A. (1996). Consequences of weight cycling in obese spontaneously hypertensive rats. American Journal of Physiology 270, R864-872.
14. ESPOSITO, G., RAPACCIUOLO, A., NAGA PRASAD, S. V., TAKAOKA, H., THOMAS, S. A., KOCH, W. J. & ROCKMAN, H. A. (2002). Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85-92.
15. 2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. Journal of Clinical Investigation 106, 1351-1359.
16. FLANAGAN, W. M., CORTHÉSY, B., BRARM, R. J. & CRABTREE, G. R. (1991). Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. Nature 352, 803-807.
17. FORCE, T., ROSENZWEIG, A., CHOUKROUN, G. & HAJJAR, R. (1999). Calcineurin inhibitors and cardiac hypertrophy. Lancet 353, 1290-1292.
18. FUENTES, J. J., GENESCÀ, L., KINGSBURY, T. J., CUNNINGHAM, K. W., PÉREZ-RIBA, M., ESTIVILL, X. & DE LA LUNA, S. (2000). DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Human Molecular Genetics 9, 1681-1690.
19. GOLDSPINK, P. H., MCKINNEY, R. D., KIMBALL, V. A., GEENEN, D. L. & BUTTRICK, P. M. (2001). Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats. Molecular and Cellular Biochemistry 226, 83-88.
20. GOODMAN, M. N., LOWELL, B., BELUR, E. & RUDERMAN, N. B. (1984). Sites of protein conservation and loss during starvation: influence of adiposity. American Journal of Physiology 246, E383-390.
21. GÖRLACH, J., FOX, D. S., CUTLER, N. S., COX, G. M., PERFECT, J. R. & HEITMAN, J. (2000). Identification and characterization of a highly conserved calcineurin binding protein, CBP1 /calcipressin, in Cryptococcus neoformans. EMBO Journal 19, 3618-3629.
22. 2+/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105, 863-875.
23. GRAEF, I. A., MERMELSTEIN, P. G., STANKUNAS, K., NEILSON, J. R., DEISSEROTH, K., TSIEN, R. W. & CRABTREE, G. R. (1999). L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 401, 703-708.
24. GRIFFITHS. E. J. & HALESTRAP, A. P. (1993). Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. Journal of Molecular and Cellular Cardiology 25,1461-1469.
25. GRIFFITHS, E. J. & HALESTRAP, A. P. (1995). Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochemical Journal 307,93-98.
26. HALESTRAP, A. P., CONNERN, C. P., GRIFFITHS, E. J. & KERR, P. M. (1997). Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Molecular and Cellular Biochemistry 174,167-172.
27. HAQ, S., CHOUKROUN, G., KANG, Z. B., RANU, H., MATSUI, T., ROSENZWEIG, A., MOLKENTIN, J. D., ALESSANDRINI, A., WOODGETT, J., HAJJAR, R., MICHAEL, A. & FORCE, T. (2000). Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. Journal of Cell Biology 151, 117-129.
28. HAQ, S., CHOUKROUN, G., LIM, H., TYMITZ, K. M., DEL MONTE, F., GWATHMEY, J., GRAZETTE, L., MICHAEL, A., HAJJAR, R., FORCE, T. & MOLKENTIN, J. D. (2001). Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103, 670-677.
29. HILL, J. A., KARIMI, M., KUTTSCHKE, W., DAVISSON, R. L., ZIMMERMAN, K., WANG, Z., KERBER, R. E. & WEISS, R. M. (2000). Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101, 2863-2869.
30. HILL, J. A., ROTHERMEL, B., YOO, K. D., CABUAY, B., DEMETROULIS, E., WEISS, R. M., KUTSCHKE, W., BASSEL-DUBY, R. & WILLIAMS, R. S. (2002). Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy: Preservation of systolic function. Journal of Biological Chemistry 277, 10251-10255.
31. HOEY. T., SUN, Y.-L., WILLIAMSON, K. & XU, X. (1995). Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity 2,461-472.
32. ICHIDA, M. & FINKEL, T. (200 1). Ras regulates NFAT3 activity in cardiac myocytes. Journal of Biological Chemistry 276, 3524-3530.
33. JANSSEN, P. M., ZEITZ, O., KEWELOH, B., SIEGEL, U., MAIER, L. S., BARCKHAUSEN, P., PIESKE, B., PRESTLE, J., LEHNART, S. E. & HASENFUSS,G. (2000). Influence of cyclosporine A on contractile function, calcium handling, and energetics in isolated human and rabbit myocardium. Cardiovascular Research 47, 99-107.
34. KÄÄB, S., DIXON, J., DUC, J., ASHEN, D., NÄBAUER, M., BEUCKELMANN, D.J., STEINBECK, G., MCKINNON, D. & TOMASELLI, G. F. (1998). Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 98, 1383-1393.
35. KATO, T., SANO, M., MIYOSHI, S., SATO, T., HAKUNO, D., ISHIDA, H., KINOSHITA-NAKAZAWA, H., FUKUDA, K. & OGAWA S. (2000). Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. Circulation Research 87, 937-945.
36. KLEE, C. B., REN, H. & WANG, X. (1998). Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. Journal of Biological Chemistry 273, 13367-13370.
37. KLEIN, I, HONG, C. & SCHREIBER, S. S. (1990). Cardiac atrophy in the heterotopically transplanted rat heart: in vitro protein synthesis. Journal of Molecular and Cellular Cardiology 22, 461-468.
38. KOLODZIEJCZYK, S. M., WANG, L., BALAZSI, K., DEREPENTIGNY, Y., KOTHARY, R. & MEGENEY, L. A. (1999). MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Current Biology 9, 1203-1206.
39. KUMAI, M., NISHII, K., NAKAMURA, K., TAKEDA, N., SUZUKI, M. & SHIBATA, Y. (2000). Loss of connexin45 causes a cushion defect in early cardiogenesis. Development 127, 3501-3512.
40. LEMASTERS, J. J., NIEMINEN, A.-L., QIAN, T., TROST, L. C. & HERMAN, B. (1997). The mitochondrial permeability transition in toxic, hypoxic and reperfusion injury. Molecular and Cellular Biochemistry 174, 159-165.
41. LEVY, D., GARRISON, R. J., SAVAGE, D. D., KANNEL, W. B. & CASTELLI, W.P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine 322,1561-1566.
42. LIM H. W., DE WINDT, L. J., MANTE, J., KIMBALL, T. R., WITT, S. A., SUSSMAN, M. A. & MOLKENTIN, J. D. (2000b). Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. Journal of Molecular and Cellular Cardiology 32, 697-709.
43. LIM, H. W., DE WINDT, L. J., STEINBERG, L., TAIGEN, T., WITT, S. A., KIMBALL, T. R. & MOLKENTIN, J. D. (2000a). Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation 101, 2431-2437.
44. LIM, H. W. & MOLKENTIN, J. D. (1999). Calcineurin and human heart failure. Nature Medicine 5, 246-247.
45. LIM, H. W. & MOLKENTIN, J. D. (2000). Reply to "Revisiting calcineurin and human heart failure". Nature Medicine 6, 3.
46. LIN, Q., SCHWARTZ, J., BUCANA, C. & OLSON, E. N. (1997). Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276, 1404-1407.
47. Luo, Z., SHYU, K.-G., GUALBERTO, A. & WALSH, K. (1998). Calcineurin inhibitors and cardiac hypertrophy. Nature Medicine 4,1092-1093.
48. MCKINSEY, T. A. & OLSON, E. N. (1999). Cardiac hypertrophy-sorting out the circuitry. Current Opinion in Genetics and Development 9, 267-274.
49. MAO, Z. & WIEDMANN, M. (1999). Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. Journal of Biological Chemistry 274, 31102-31107.
50. MEGURO, T., HONG, C., ASAI, K., TAKAGI, G., MCKINSEY, T. A., OLSON, E.N. & VATNER, S. F. (1999). Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circulation Research 84, 735-740.
51. q leads to hypertrophy and dilated cardiormopathy by calcineurin-dependent and independent pathways. Proceedings of the National Academy of Sciences of the USA 95, 13893-13898.
52. MESAELI, N., NAKAMURA, K., ZVARITCH, E., DICKIE, P., DZIAK, E., KRAUSE, K.-H., OPAS M., MACLENNAN, D. H. & MICHALAK, M. (1999). Calreticulin is essential for cardiac development. Journal of Cell Biology 144, 857-868.
53. MOLKENTIN, J. D. (2000). Calcineurin and beyond: cardiac hypertrophic signaling. Circulation Research 87, 731-738.
54. MOLKENTIN, J. D. (2001). Calcineurin, mitochondrial membrane potential, and cardiornyocyte apoptosis. Circulation Research 88, 1220-1222.
55. MOLKENTIN, J. D. & DORN, G. W. II (2001). Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annual Review of Physiology 63, 391-426.
56. MOLKENTIN, J. D., LU, J.-R., ANTOS, C. L., MARKHAM, B., RICHARDSON, J., ROBBINS, J., GRANT, S. R. & OLSON, E. N. (1998). A calcineurin-dependent transcription pathway for cardiac hypertrophy. Cell 93, 215-228.
57. MORIMOTO, T., HASEGAWA, K., WADA, H., KAKITA, T., KABURAGI, S., YANAZUME, T. & SASAYAMA, S. (2001). Calcineurin-GATA4 pathway is involved in, β-adrenergic agonist-responsive endothelin- 1 transcription in cardiac myocytes. Journal of Biological Chemistry 276, 34983-34989.
58. MULLER, J. G., NEMOTO, S., LASER, M., CARABELLO, B. A. & MENICK, D. R. (1998). Calcineurin inhibition and cardiac hypertrophy. Science 282, 1007 (letter).
59. MURAT, A., PELLIEUX, C., BRUNNER, H.-R. & PEDRAZZINI, T. (2000). Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. Journal of Biological Chemistry 275, 40867-40873.
60. MUSARÒ, A., McCULLAGH K. J. A., NAYA, F. J., OLSON, E. N. & ROSENTHAL, N. (1999). IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400,581-585.
61. NAZARETH, W., YAFEI, N. & CROMPTON, M. (1991). Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A. Journal of Molecular and Cellular Cardiology 23, 1351-1354.
62. NEAL, J. W. & CLIPSTONE, N. A. (200 1). Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. Journal of Biological Chemistry 276, 3666-3673.
63. NEILSON, J., STANKUNAS, K. & CRABTREE, G. R. (2001). Monitoring the duration of antigen-receptor occupancy by calcineurin/glycogensynthase-kinase-3 control of NF-AT nuclear shuttling. Current Opinion in Immunology 13, 346-350.
64. OAKLEY, D. (2001). The athlete's heart. Heart 86, 722-726.
65. OLSON, E. N. & MOLKENTIN, J. D. (1999). Prevention of cardiac hypertrophyby calcineurin inhibition: hope or hype? Circulation Research 84,623-632.
66. OUKKA, M., HO, I.-C., DE LA BROUSSE, F. C., HOEY, T., GRUSBY, M. J. & GLIMCHER, G. R. (1998). The transcription factor NFAT4 is involved in the generation and survival of T cells. Immunity 9, 295-304.
67. 2+-release channel in cardiac sarcoplasmic reticulum. American Journal of Physiology 45, H865-872.
68. PASSIER, R., ZENG, H., FREY, N., NAYA, F. J., NICOL, R. L., McKINSEY,T. A., OVERBEEK, P., RICHARDSON, J. A., GRANT, S. R. & OLSON, E. N. (2000). CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. Journal of Clinical Investigation 105, 1395-1406.
69. RANGER, A. M., GRUSBY, M. J., HODGE, M. R., GRAVALLESE, E. M., DE LA BROUSSE, F. C., HOEY, T., MICkANIN, C., BALDWIN, H. S. & GLIMCHER, L. H. (1998). The transcription factor NF-ATc is essential for cardiac valve formation. Nature 392, 186-190.
70. RAO, A., LUO, C. & HOGAN, P. G. (1997). Transcription factors of the NFAT family: regulation and function. Annual Review of Immunology 15, 707-747.
71. ROTHERMEL, B. A., MCKINSEY, T. A., VEGA, R. B., NICOL, R. L., MAMMEN,P., YANG, J., ANTOS, C. L., SHELTON, J. M., BASSEL-DUBY, R., OLSON, E.N. & WILLLAMS, R. S. (2001). Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proceedings of the National Academy of Sciences of the USA 98, 3328-3333.
72. ROTHERMEL, B. A., VEGA, R. B., YANG, J., WU, H., BASSEL-DUBY, R. & WILLIAMS, R. S. (2000). A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. Journal of Biological Chemistry 275, 8719-8725.
73. SAKATA, Y., MASUYAMA, T., YAMAMOTO, K., NISHIKAWA, N., YAMAMOTO,H., KONDO, H., ONO, K., OTSU, K., KUZUYA, T., MIWA, T., TAKEDA, H., MIYAMOTO, E. & HORI, M. (2000). Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 102, 2269-2275.
74. 2+-dependent calcineurin signalling pathway. Nature 400, 576-581.
75. SERNERI, G. G. N., BODDI, M., MODESTI, P. A., CECIONI, I., COPPO, M., PADELETTI, L., MICHELUCCI, A., COLELLA, A. & GALANTI, G. (2001). Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circulation Research 89, 977-982.
76. SHIBASAKI, F., PRICE, E. R., MILAN, D. & MCKEON, F. (1996). Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Nature 382, 370-373.
77. SHIMOYAMA, M., HAYASHI, D., TAKIMOTO, E., ZOU, Y., OKA, T., UOZUMI, H., KUDOH, S., SHIBASALKI, F., YAZAKI, Y., NAGAI, R. & KOMURO, I. (1999). Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 100, 2449-2454.
78. SHIMOYAMA, M., HAYASHI, D., ZOU, Y., TAKIMOTO, E., MIZUKAMI, M., MONZEN, K., KUDOH, S., HIROI, Y., YAZAKI, Y., NAGAI, R. & KOMURO, I. (2000). Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension. Circulation 102, 1996-2004.
79. SOHAL, D. S., NGHIEM, M., CRACKOWER, M. A., WITT, S. A., KIMBALL, T. R., TYMITZ, K. M., PENNINGER, J. M. & MOLKENTIN, J. D. (2001). Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible cre protein. Circulation Research 89,20-25.
80. STEINBERG, S. F. (2000). Many pathways to cardiac hypertrophy. Journal of Molecular and Cellular Cardiology 32, 1381-1384.
81. SUSSMAN, M. A., LIM, H. W., GUDE, N., TAIGEN, T., OLSON, E. N. ROBBINS, J., COLBERT, M. C., GUALBERTO, A., WIECZOREK, D. F. & MOLKENTIN, J. D. (1998). Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281, 1690-1693.
82. TAIGEN, T., DE WINDT, L. J., LIM, H. W. & MOLKENTIN, J. D. (2000). Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences of the USA 97, 1196-1201.
83. TSAO, L., NEVILLE, C., MUSARO, A., MCCULLAGH, K. J. A. & ROSENTHAL, N. (2000). Revisiting calcineurin and human heart failure. Nature Medicine 6, 2-3.
84. WANG, Z., KUTSCHKE, W., RICHARDSON, K. E., KARIMI, M. & HILL, J. A. (2001a). Electrical remodeling in pressure-overload cardiac hypertrophy: role of calcineurin. Circulation 104, 1657-1663.
85. 2+ exchanger remodeling in pressure overload cardiac hypertrophy. Journal of Biological Chemistry 276, 17706-17711.
86. WU, H., NAYA, F. J., MCKINSEY, T. A., MERCER, B., SHELTON, J. M., CHIN, E. R., SIMARD, A. R., MICHEL, R. N., BASSEL-DUBY, R., OLSON, E. N. & WILLIAMS, R. S. (2000). MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type. EMBO Journal 19,1963-1973.
87. WU, H., ROTHERMEL, B., KANATOUS, S., ROSENBERG, P., NAYA, F. J., SHELTON, J. M., HUTCHESON, K. A., DIMAIO, J. M., OLSON, E. N., BASSEL-DUBY, R. & WILLIAMS, R. S. (2001). Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO Journal 20, 6414-6423.
88. XIA, Y., MCMILLIN, J. B., LEWIS, A., MOORE, M., ZHU, W. G., WILLIAMS, R. S. & KELLEMS, R. E. (2000). Electrical stimulation of neonatal cardiac myocytes activates the NFAT3 and GATA4 pathways and upregulates the adenylosuccinate synthetase 1 gene. Journal of Biological Chemistry 275, 1855-1863.
89. YANG, J., ROTHERMEL, B., VEGA, R. B., FREY, N., MCKINSEY, T. A., OLSON, E. N., BASSEL-DUBY, R. & WILLIAMS, R. S. (2000). Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circulation Research 87, e61-e68.
90. 2+ channel currents in cardiac hypertrophy induced by activation of calcineurin-dependent pathway. Journal of Molecular and Cellular Cardiology 33, 249-259.
91. YOUN, H.-D., CHATILA, T. A. & LIU, J. O. (2000). Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO Journal 19,4323-433 1.
92. ZENG, H., CHATTARJI, S., BARBAROSIE, M., RONDI-REIG, L., PHILPOT, B. D., MIYAKAWA, T., BEAR, M. F. & TONEGAWA, S. (2001). Forebrain-specific calcineurin knockout selectively impairs bidirectinal synaptic plasticity and working/episodic-like memory. Cell 107, 617-629.
93. ZHANG, W., KOWAL, R. C., RUSNAK, F., SIKKINK, R. A., OLSON, E. N. & VICTOR, R. G. (1999). Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circulation Research 84, 722-728.
94. ZHU, J. & MCKEON, F. (1999). NF-AT activation requires suppression of Crm1-dependent export by calcineurin. Nature 398,256-260.
95. ZOU, Y., HIROI, Y., UOZUMI, H., TAKIMOTO, E., TOKO, H., ZHU, W., KUDOH, S., MIZUKAMI, M., SHIMOYAMA, M., SHIBASAKI, F., NAGAI, R., YAZAKI, Y. & KOMURO, I. (2001a). Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 104,9 7-101.
96. ZOU, Y., YAO, A., ZHU, W., KUDOH, S., HIROI, Y., SHIMOYAMA, M., UOZUMI, H., KOHMOTO, O., TAKAHASHI, T., SHIBASAKI, F., NAGAI, R., YAZAKI, Y. & KOMURO, I. (2001b). Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin. Circulation 104,102-108.